Study to treat deadly form of thyroid cancer shows promise
- Posted: April 19, 2013
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial. The collaborative study, published in the April 16 online issue of the Journal of Clinical Endocrinology & Metabolism, reports that combining paclitaxel chemotherapy with an experimental agent known as efatutazone was safe and well tolerated by patients. Organizations participating in the study were: the Mayo Clinic, the University of Pennsylvania Abramson Cancer Center, Eastern Virginia University, the Dana-Farber Cancer Institute, Ohio State University (home to the OSU Comprehensive Cancer Center), the University of Oregon Medical Center (home to the Knight Cancer Institute), the University of Colorado School of Medicine (home to the University of Colorado Cancer Center), Emory University Hospital (home of the Winship Cancer Institute), Weill Cornell Medical College, and Japanese pharmaceutical company, Daiichi Sankyo.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.